# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Statistically significant (p=0.0177) reduction in knee pain at six monthsStatistically significant (p<0.0001) maintenance o...
Cantor Fitzgerald analyst Ross Osborn reiterates Organogenesis Hldgs (NASDAQ:ORGO) with a Overweight and maintains $5 price ...
Organogenesis Hldgs (NASDAQ:ORGO) reported quarterly earnings of $0.010 per share which met the analyst consensus estimate. Th...